Information Provided By: 
Fly News Breaks for September 30, 2019
XENT, SWAV, GKOS
Sep 30, 2019 | 09:29 EDT
BofA/Merrill analyst Bob Hopkins double downgraded Glaukos (GKOS) to Underperform from Buy and lowered his price target for the shares to $67 from $75. The analyst remains bullish on the company's long term prospects and sees no issues with its Q3 and Q4 results, but he prefers other names in the space given the potential distraction associated with the integration of Avedro. Hopkins also lowered his price target for ShockWave Medical (SWAV) to $40 from $64 and for Intersect ENT (XENT) to $22 from $39.
News For GKOS;SWAV;XENT From the Last 2 Days
There are no results for your query GKOS;SWAV;XENT
